NRS2002在胃癌新辅助化疗患者术前营养筛查的应用

目的：探讨NRS2002营养不良风险筛查法对于接受新辅助治疗胃癌患者进行术前营养评估的应用价值 方法：选取63例接受新辅助治疗的胃癌患者，应用NRS2002营养筛查工具对其进行营养风险评估，按NRS2002评分≥3定义为存在营养风险组，<3分为营养正常组。测定患者各项临床指标及术后感染并发症、平均住院天数等与NRS评分的关系，同时以前白蛋白水平为指标，测定NRS2002在胃癌新辅助治疗患者中营养筛查的敏感度、特异度及准确率 结果：经NRS2002评分后发现23例患者存在营养风险（63.5%），营养正常组40例（36.5%），化疗-手术间期在4周以内的患者容易出现营养不良，营养风险组的患者BMI指数、白蛋白、前白蛋白水平、淋巴细胞计数均低于营养正常组，营养风险组住院天数较营养正常组延长，腹腔感染的发生率高于营养组。以前白蛋白为指标，NRS2002筛选营养不良的特异度为87.8%；灵敏度为81.8%；准确率为85.7% 结论：接受新辅助治疗的胃癌患者容易合并营养不良，营养不良可能对患者术后恢复造成不利影响，而NRS2002是一个相对简便快速的营养筛查工具，有一定的实用价值。

The use of NRS2002 in screening nutritional risk in gastric cancer patients receiving neoadjuvant chemotherapy

Objective: to assess the application of NRS 2002 in in screening nutritional risk in gastric cancer patients receiving neoadjuvant chemotherapy Methods: 63 gastric cancer patients with neoadjuvant chemotherapy were included. According to the results from NRS2002, NRS score equal to or over 3 were defined as with nutritional risk and less than 3 as normal. Clinical parameters, postoperative infection and hospital stay of the patients were recorded to analyze their relationship with NRS score. Meanwhile, pre-album level was also examined to evaluate the sensitivity, specificity and accuracy of NRS2002 in nutritional risk screening. Results: 23 patients were identified as with nutritional risk and 40 as normal. Patients with a chemotherapy-operation-interval within 4 weeks were vulnerable to malnutrition. Patients with high nutritional risk present a relative lower BMI index, album level, pre-album level, lymphocyte number compared with the normal patients. With serum pre-album as an indicator, NRS2002 had a specificity of 87.8%, a sensitivity of 81.8% and accuracy of 85.7%. Conclusion: patients receiving neoadjuvant chemotherapy are vulnerable to malnutrition. Malnutrition may exert an unfavorable effect on postoperative recovery. NRS2002 is a relatively valuable in screening nutritional risk for its feasibility.